Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiopinac is a tricyclic non-steroidal anti-inflammatory drug (NSAID) with demonstrated anti-inflammatory and analgesic effects. Its mechanism of action involves the inhibition of prostaglandin synthesis, which contributes to its ability to reduce inflammation and pain. Tiopinac has been studied in clinical settings for conditions such as rheumatoid arthritis, where it showed efficacy in reducing symptoms like walking time, painful joints, morning stiffness, and increasing grip strength. However, development was discontinued due to toxicity observed at higher doses. The compound modulates key inflammatory mediators and pathways—including pro-inflammatory cytokines—and reduces oxidative stress in biological systems[6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tiopinac.